EGFR Resisters has teamed up with 23andMe on the Lung Cancer Genetics Study
Jill Feldman shared a post by EGFR Resisters on X, adding:
“I am grateful for all the advancements in lung cancer research and treatment, but it isn’t moving fast enough!
No single institution, researcher, or company will ever have enough or share the data needed to answer critical questions NOW.
That is why the lung cancer community—patients, advocates, doctors, and researchers—has come together; to urgently and determinedly accelerate research!”
Quoting EGFR Resisters post:
“EGFR Resisters has teamed up with 23andMe on the Lung Cancer Genetics Study.
The goal: To learn more about the genetics of people living with lung cancer in an effort to advance treatment discoveries.
Sign up here.”
Source: Jill Feldman/X and EGFR Resisters/X
Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board.
Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023